Clinical trial · Interventional
Low-dose Radiotherapy in iNHL
Low-dose Radiotherapy in Indolent Lymphoma：A Multi-center Phase II Study
NCT05543070CI-TRIAL-00060906unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of low-dose radiotherapy (3 Gy\*4f) in indolent lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Indolent Lymphoma | Indolent Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Low-dose Radiotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Low-dose radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Low-dose Radiotherapy
- description
- Involved-site radiotherapy (3 Gy\*4f) in one week
- interventionNames
- Radiation: Low-dose radiotherapy
Primary outcomes (1)
- measure
- Rate of clinical complete response after radiotherapy
- timeFrame
- 6-month after radiotherapy
- description
- complete resolution of disease in imaging or biopsy after low-dose radiotherapy
Secondary outcomes (6)
- measure
- Overall response rate after radiotherapy
- timeFrame
- 6-month after radiotherapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathology proved iNHL * ECOG PS ≤3 * Signed Informed consent Exclusion Criteria: * History of radiotherapy at the same site * Primary malignant lymphoma of the gastrointestinal tract * CTV (Clinical Target Volume)\>500ml * Others that researchers consider inappropriate
References
Publications (2)
- DERIVEDWang XY, Zhang XM, Wang L, Gao LR, Chen K, Feng XL, Rao W, Zheng R, Wu YP, Song YW, Fang H, Chen B, Jin J, Liu YP, Jing H, Tang Y, Zhang WW, Zhai YR, Lu NN, Li N, Xia CF, Wang SL, Liu X, Li YX, Qi SN. Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025 Jun;12(6):e442-e450. doi: 10.1016/S2352-3026(25)00071-7. Epub 2025 May 2. PMID 40324445
- DERIVEDGao LR, Wang X, Xia C, Song YW, Wang L, Li X, Yang Y, Cao JZ, Chen K, Zhong QZ, Gao Y, Zhou SY, Feng XL, Wang X, Li YX, Qi SN. Multicenter phase II study of moderate low-dose radiotherapy in indolent non-Hodgkin lymphoma: CLCG-iNHL-01 protocol. Future Oncol. 2024 Jan;20(2):71-81. doi: 10.2217/fon-2023-0761. Epub 2024 Jan 5. PMID 38179936